David Hung, M.D., is a distinguished leader in the biotechnology industry, currently serving as the President and Chief Executive Officer at NUVATION BIO INC CLASS A. Dr. Hung's career is marked by a deep commitment to advancing medical science and improving patient outcomes. He earned his medical degree from the University of California, San Francisco, and has since built an impressive track record in drug development and corporate leadership. Prior to his role at NUVATION BIO, Dr. Hung held key positions at several notable biotech firms, including Medivation, where he played a pivotal role in the development and commercialization of groundbreaking cancer treatments. At NUVATION BIO, Dr. Hung has been instrumental in steering the company towards its mission of developing novel therapies for cancer patients. Under his leadership, the company has focused on creating a robust pipeline of drug candidates that target specific cancer pathways, aiming to provide more effective and personalized treatment options. His strategic vision and ability to foster a culture of innovation have been critical to the company's growth and success. Dr. Hung's extensive experience in oncology and his dedication to advancing cancer research have positioned NUVATION BIO as a leader in the field. In addition to his corporate responsibilities, Dr. Hung is actively involved in the broader scientific community, often sharing his insights and expertise through various platforms. His contributions to the field have been recognized with numerous awards and accolades, reflecting his impact on both the industry and patient care. As he continues to lead NUVATION BIO, Dr. Hung remains focused on driving the company's mission forward, leveraging his passion for science and commitment to improving the lives of those affected by cancer.